Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Shandong Boan Biotechnology Co. Ltd. currently manages a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action across its active filings. This workload is handled by 1 distinct examiner, indicating a concentrated prosecution pipeline at this stage. Such concentration often simplifies the management of intellectual property as it limits the number of examiner interactions required to advance the portfolio.
The prosecution activity is limited to 1 distinct art unit. JUEDES, AMY E is identified as the busiest examiner for the portfolio. This examiner is responsible for 1 pending office action, which represents the entirety of the company's current pending workload. The alignment of 1 distinct examiner to 1 distinct art unit suggests a narrow technical focus for the pending matters. For a practitioner, this means that the outcome of the entire pending portfolio currently rests on the decisions of the individual examiner within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019179 | STEALTH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF IN REDUCING CYTOTOXICITY TOWARDS NORMAL CELLS | JUEDES, AMY E | 3d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019179 | STEALTH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF IN REDUCING CYTOTOXICITY TOWARDS NORMAL CELLS | JUEDES, AMY E | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18019179 | STEALTH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF IN REDUCING CYTOTOXICITY TOWARDS NORMAL CELLS | JUEDES, AMY E | 1644 | §102§103§112 | Non-Final OA | 3d overdue | Pending | Feb 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial